Who should attend the AseBio Investor Day?

Investors & Financial Organizations

  • Venture Capital and other private investment platforms
  • Pharmaceutical & Industrial Companies
  • Business Angels & Family Offices
  • Corporate Venture Capital
  • Investment Banks & Financial Services Companies

Innovative Companies & Institutions

  • Executives from innovative biotech companies from all areas of biotechnology (Life Sciences, Agritech, Industrial)
  • Research & Academic Institutions
  • Non-profit organizations
  • Government Organizations

This event is intended for companies actively seeking investment as well as investors looking for funding. Service providers including law, accounting and consulting firms, contract manufacturers, active pharmaceutical ingredient manufacturers, contract research organizations, real estate development companies etc. will be allowed to attend on a one-to-one basis as approved by AseBio. If you are a service company and you’re interested in making use of the partnering system, we have exclusive sponsorship opportunities including this possibility. Please contact us: Stuart Medina–

Confirmed Investors


3B Future Health Fund supports US and European-based private early-stage, innovative companies in areas of high unmet patient needs.

The Fund currently made investments in 20+ promising start-ups advancing novel therapies in areas of high unmet medical need. During the first three years, the Fund registered its first exit, the EUR 425 million acquisition of AMAL Therapeutics by a top tier pharmaceutical company in 2019.

In 2020, the Fund was re-branded 3B Future Health Fund and launched in Oncology and Rare Disease Therapeutics.

The 3B Future Health Fund II is backed by the same proven team with the industry experience and network to advance promising projects from preclinical stage to the clinic and beyond. The team is motivated by the success of the first fund and united in its desire to provide transformative treatments for patients with cancer or rare diseases.


AdBio Partners (formerly Advent France Biotechnology) is a venture capital firm investing in early-stage life sciences companies in Europe.

AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth.


Andera Partners is an asset management firm specialising in Private Equity. We draw on our expertise in various areas to provide a range of well-defined investment strategies. Our goal is to provide bespoke solutions to meet the challenges faced by leaders and their business models.

Companies must face multiple challenges to innovate, grow and adapt to a rapidly changing environment. It has been Andera Partners’ mission for over 20 years to help companies and their management achieve strong and sustainable growth.


Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.


AurorA Science is the result of the partnership between the technology transfer company AurorA-TT and two strategic industrial partners and investors, Rottapharm Biotech and Italfarmaco, who share in-house R&D facilities and expertise to support the development of portfolio companies and create the ideal conditions for partnering with bio-pharma companies.

Investment size will vary in a range of €1 to 5M per deal to support the final pre-clinical activities and the early clinical developments.






Capsa Food, leader in the dairy sector has an open innovation unit, whose purpose is the long-term transformation of CAPSA FOOD, with two specific objectives: to improve the adoption of key technology for the transformation of the business and the exploration of new growth drivers. It has two areas of activity, the Capsa Vida project, with the objective of investing in start-ups with which to develop new technological solutions and new ingredients that improve people’s nutrition and quality of life, as well as the development of new consumer products. It also has the LaGranja_Lab project, whose specific objective is to transform the rural environment by applying the best technological solutions for food with a better environmental and social impact.


Founded in 2013 in Barcelona, Inveniam Group is a boutique consulting firm dedicated to elevating innovations from concept to market. Specializing in financial advisory, strategic consulting and public funding access, we operate across life sciences and sustainability sectors. Our expertise has established us as leaders in delivering transformative outcomes for startups and researchers, and in assisting corporate and public institutions.


Checkpoint Partners is a Madrid based specialist investment and advisory company specialized in Life Sciences, Energy and ICT.


Clave Mayor is a venture capital firm, focused on tech transfer projects mainly in Spain. We manage currently several funds with a total volume of more than 90 million euros to invest in different sectors, one of which is Health, counting on not only biotech projects but also and more precisely, Applied Technologies Spinoffs/Startups referred to Medical Devices, mHealth, e-Healt and Health Nutrition.

Our purpose is to invest after the Proof of Concept (TRLs 4-9), in dealflow coming from Universities, Research Centers, or other origins, in a very early stage, even taking part in the settlement of the companies (or during the first years) and supporting the startups generating value, not only from a financial or legal perspective but also in fulfilling their strategic goals, thanks to our background investing in Health and also to the involvement of some of our Limited Partners, who are already players in the sector.

Clave Mayor was launched in 2002 in Pamplona (North of Spain) where we have our Headquarters. We currently have also branch offices in Madrid and Valencia, and we have managed during these 20 years more than a 150MM€.


Criteria Bio Ventures is a leading life sciences venture fund looking to partner with transformative companies to shape the future of healthcare. We team up with driven entrepreneurs and fellow investors who aim to revolutionize healthcare through disruptive and well-protected innovations that have the potential to transform patients’ lives where there is a significant unmet medical need. We invest in private biotech companies in Europe and North America, with special focus in Spain and Portugal. We invest agnostically across therapeutic modalities and disease areas, offering evergreen support until achieving meaningful impact. Criteria Bio Ventures is part of Caixa Capital Risc and the CriteriaCaixa group, Spanish largest investment holding with €25+ Bn assets under management.


At Double Helix our mission is to identify and invest Industrial Biotech companies with high growth potential within the Industrial Biotech sectors, focus on:

  • Diagnostics and Preemptive Health (advancements that redefine early detection and preventive healthcare solutions);
  • Life Science Tools (groundbreaking tools that accelerate research and development in life sciences);
  • AI for Life Science (AI innovations that enhance data analytics, research methodologies, and patient outcomes in life sciences).

EIB / EIC Fund, Luxembourg

The EIC Fund is the venture arm of the European Innovation Council (EIC). It was set up as a capital fund under private law with the European Commission as a shareholder to fund companies selected under the EIC Accelerator.

With a budget of over €10 billion, the European Innovation Council (EIC) is strengthening Europe’s leadership in deep tech innovation by generating a pipeline of startups with the potential to become unicorns.

The EIC Fund is bridging the funding gap for deep tech European startups that have market-creating potential but carry a high risk for private and public investors. The EIC Fund supports these companies with patient capital to minimize this risk.


Created by and for companies, ELKARGI is a Guarantee Society (SGR), with more than 40 years improving conditions of loans given by banks to SMEs and the self-employed, thereby facilitating the access to real financing.

With more than 5.600 partner companies, we are the leading guarantee society in all Spain by volume of guarantees granteds, with offices in Bilbao, San Sebastian, Pamplona and Vitoria-Gasteiz.


Euronext is the leading European stock exchange with an unparallel reach across the continent with presence in 10 countries, +1900 listed companies and an active base of institutional investors from more than 50 countries. Euronext represents a unique platform for Tech companies with more than 700 listed companies, of which ca.110 are in the Life Science segment.


FAES Farma is a pharmaceutical company with more than 90 years of experience in the research, production, and commercialization of pharmaceutical products around the globe. FAES Farma has created a dedicated unit focusing on the scouting and evaluation of investment opportunities, with the goal of significantly expanding its Drug Discovery portfolio, contributing to our goal of improving patients’ health by making new innovative pharmaceutical solutions.



The Botin Foundation contributes to the integral development of society by exploring new ways of detecting creative talent, committing to the above to generate wealth.

Created in 2011, the  programme Mind the Gap promotes biotechnology entrepreneurship to enable technologies with commercial potential, developed by Spanish scientific institutions, to reach the market to generate social and economic development. Its objective is to bridge the gap that separates science from business and society.

To this end, the Mind the Gap programme selects incipient business projects based on technologies in the life sciences area generated in Spanish research institutions.


With 27 years of experience in investment, we are a multi-asset manager with a broad offering for different types of investors, based on risk and volatility. Within the different investment strategies – Infrastructure, Venture Capital and Private Equity -, we have launched a new strategy focus on healthcare companies in a crucial growth phase to help them scale and unlock their full growth potential. GED has a long and successful track record of investing in Healthcare and has built an extensive network with key players in the global healthcare industry, becoming a support for the companies’ business development that we invest in. This new strategy invests in companies with no technological or scientific risk and minimal regulatory uncertainties, with the aim of supporting them in the next stages of production and commercialization.  


Our specialized Grifols Innovation and New Technologies group, GIANT, is the company’s external innovation arm, dedicated to diversifying Grifols’ external partnerships and investments to identify and develop strategic business opportunities.

Comprised of scientists and business professionals with expertise in drug discovery and development, GIANT acts as a corporate venture partner, scouting and evaluating opportunities in new therapies and technology platforms with the potential to complement the existing Grifols portfolio. It then manages investee companies and collaborations to ensure impactful contribution to the furthering of our mission.


Hadean Ventures is a European life science VC fund manager with approx . EUR 230m assets under management. We invest across all healthcare verticals and stages; in products with the potential to address unmet medical needs.


Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle.

Founded in 2008, Inveready counts on 210 active companies, 64 exits and more than €1,2bn of assets under management.

Some of our portfolio companies have been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth.

In 2023 Inveready raised its 4th Life Sciences dedicated fund with +58 M€ aiming to invest in 20 companies in Spain mainly, but also in Europe and North America. 


Invivo Partners is a venture capital firm specializing in early-stage life sciences companies.

It is managed by Luis Pareras, Albert Ferrer, and Laura Rodríguez, boasting investments in 15 portfolio companies and three funds under management. The firm recently announced its third fund, targeting €100 million for investment in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. The initial investment ticket ranges from €2 million to €4 million, with follow-on investments in portfolio companies of up to €10 million per company after meeting specific.


Korion is a specialized venture capital fund focused on investing in the best firms in the Life Sciences sector in the United States, Europe, and Israel.

Korion is a venture capital fund of funds that provides institutional and individual investors with access to unique investment opportunities that are not readily available to most investors.

Korion was founded to invest in the most socially impactful and highest performing firms in the life sciences sector. Our investments span the biomedical, digital health, and medical technology sectors, typically during the early stages of company development.

M VENTURES, Netherlands

M Ventures is the strategic, corporate venture capital fund of Merck, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.

We invest – with dual strategic and financial foci – into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.

We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.

MSD, United Kingdom

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide.  From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. We operate in more than 140 countries and had sales of more than $60 billion in 2023. Through our BD&L team we invest in innovation, both as partner (  as well as corporate investor (


Namarel Ventures is an early-stage investment firm specialized in the healthcare sector. We provide investment and support to innovative, data-driven companies that address an unmet medical need in the fields of medical devices, diagnostics and digital health.

Namarel looks for committed entrepreneurs to work together and enjoy along the journey towards the market. We prioritize those projects to which we can be an active investor by leveraging our understanding and experience to contribute to the healthcare sector. We don’t have territory constrains but we mainly invest in Spain.


Noso Capital is founded by a multidisciplinary team that pursues the goal of promoting companies in the long term and in the challenges of Industry 4.0, ESG and Globalization in the current economy. Is a pioneer in integrating technology experts and investing in companies that face important challenges in the global economic or technological environment or some extraordinary strategic, operational or financial situation.

Noso Capital’s philosophy is based on identifying high growth potentialities that require not only capital, but also and fundamentally professional support in management, providing value and results, with management, technological transformation, internationalization and adaptation to globalization, as levers of investment value creation. Technology is key and plays a very important role in our philosophy, as a lever to generate value and sustainability.


Pioneer Group operates several funds that invest in young businesses and specialise in pre-seed funding.

We like to get involved early. Pioneer Group provides vital life sciences investment and funding primarily to companies that we have worked with through our Accelerator Programme activity or with companies based at our sites across the UK. That way, we get to know the people, technology and business well before investing.

Having said that, we will also look at any great opportunities with game changing technology, so feel free to get in touch- no matter how early you are in the process.

QUAN CAPITAL, China & United States

Quan Capital is a life sciences venture capital firm with strong China expertise and global capabilities. We discover, incubate and grow next-generation life science companies in early and growth stage, worldwide. Our portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.

Quan has offices in Shanghai and Palo Alto. Our investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and they leverage their broad network worldwide to help maximize the company’s value across geographies and development stages.


Swanlaab is Venture Capital firm managing among other funds, the Swanlaab Agrifood-tech fund I, investing in in the agrifood tech sector targeting projects that strategically align with the global value chain of the agricultural and food industry.


Sodena is the instrument of the Government of Navarra for attracting and developing value-added business projects, contributing to regional development and the creation of quality employment.

Venture capital is Sodena’s main financial instrument for dealing with investment projects. Sodena is an active Venture Capital partner, which supports the management of its investee companies, is involved in decision-making on the board of directors and makes its extensive network of contacts available to the companies.


Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines in specialty therapeutics areas.

Sound Bioventures Fund I AB is a registered alternative investment fund, under the Swedish Alternative Investment Funds Managers Act. 


TECH TRANSFER AGRIFOOD (TTAF) operates as an investment platform focusing on supporting startups and high-impact technologies within the food and beverage supply chain. Positioned as the first venture capital fund addressing industry demands, TTAF aims to bridge the gap between innovation and market needs. By facilitating connections between technological supply and industry demand, this fund offers a specialized investment avenue tailored to the Agri-Food Sector.


Founded in 2013, YAFO Capital is a Shanghai based boutique investment & advisory firm focusing on bringing global technologies to Asia. We started from investing in Israeli Medtech to China back to 2013, YAFO has established four joint ventures with our global partners in Japan, Italy, Germany, and Switzerland.

YAFO has four pillar business lines including: investment banking, fund investment, incubation, and biotech forum. YAFO, the Hebrew word of Jaffa (now part of Tel Aviv), means beautiful. For 3500 years, the old Jaffa port has connected the ancient city with the rest of the world.

YAFO’s mission is to make our life more beautiful by introducing global technologies.


Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over $450 million in assets under management through its three funds.


Empowering Tech Innovation

Specialized financial solutions for the tech industry and investors

Confirmed Participants

3B Future Health Ventures, Monaco
Abanza Tecnomed, Spain
Abbvie, Germany
Ability Pharmaceuticals, Spain
Adamo Robot, Spain
AdBio Partners, Spain
AdBio Partners, France
ADmit Therapeutics, Spain
ADNTRO Genetics, Spain
Agency for Science, Technology and Research, Singapore
Agio Capital & Novas Ventures, Belgium
Allinky Biopharma, Spain
AMS Biopharma Laboratory SLU, Spain
Andera Partners, France
Anquor, Spain
Aquilon Cyl, Spain
Ardena, Spain
Asabys Partners, Spain
AseBio - Spanish Bioindustry Association, Spain
Asociación Instituto de Investigación Sanitaria Biogipuzkoa, Spain
Atrys Health, Spain
AUM Biosciences Pte Ltd, Singapore
AurorA Science, Italy
Ayming España, Spain
Banco Sabadell, Spain
Batea Oncology, Spain
Basque Health Cluster, Spain
Betternostics SL, Spain
BIC Gipuzkoa Berrilan, Spain
Biobide (BIAT Group), Spain
Biocat, Spain
BioCentury, United States
Bioga, Spain
Biovance Capital, United Kingdom
BME Growth, Spain
Bolsas y Mercados Españoles (BME), Spain
Bread Free, Spain
Burdinola, Spain
Business Angel - María Arbulu, Spain
Business Angel - Miguel Ángel Pérez, Spain
CaixaBank DayOne, Spain
Capital Cell, Spain
Capsa Food, Spain
Cartago Ventures, Spain
CEEI Asturias, Spain
CEIN, Spain
Celavista Laboratories, Spain
CELLAB, Andorra
Celldrive 3D S.L., Spain
Checkpoint Partners, Spain
CIC bioGUNE, Spain
CIC biomaGUNE, Spain
CIC nanoGUNE, Spain
Citibank, Spain
Clarke, Modet y Cía. S.L., Spain
Clave Mayor, Spain
Columbus Venture Partners, Spain
Copal Scientific, Spain
Criteria Bio Ventures, Spain
Cultzyme, Spain
DIVE Medical, Spain
Doctomatic, Spain
Double Helix, Spain
EIB / EIC Fund, Luxembourg
Elkargi SGR, Spain
Euronext, France
Eversheds Sutherland, Spain
Faes Farma, Spain
First and Last Project, Spain
Flomics Biotech, Spain
Fortrea, Spain
Fundació Hospital Universitari Vall Hebron - Institut de Recerca, Spain
Fundación Botín, Spain
Fundación Tecnalia, Spain
Fundación Vicomtech, Spain
Gate2Brain S.L., Spain
GED Capital, Spain
Genbioma, Spain
Genesis Biomed, Spain
Grifols, Spain
GSK, Spain
Hadean Ventures, Norway
I+MED, S.COOP., Spain
I3PT, Spain
ICEX-Invest in Spain, Spain
INBENTUS Medical Technology, Spain
Ingredalia SL, Spain
Inhibitec Anticuerpos S.L., Spain
InnoUp Farma, Spain
Integra Therapeutics, Spain
Inveniam Group, Spain
Inveready, Spain
Invivo Partners, Spain
ITEMAS Network, Spain
Kaudal, Spain
KisoJi Biotechnology Inc., Canada
Konexio Biotech, Spain
Korion Life Sciences, Spain
Labcorp Laboratories S.L., Spain
Laboratorio Reig Jofre S.A., Spain
Laminar Pharmaceuticals SA, Spain
Leadartis, Spain
Leanbio, Spain
Life Science Nation, United States
LKS Financial Solutions & Corporate, Spain
M:M Bio, United Kingdom
M Ventures, Germany
M Ventures, Netherlands
Microviable Therapeutics, Spain
Mikrobiomik Healthcare, Spain
MIMO Biosciences, Spain
Miramoon Pharma, Spain
MiWEndo Solution, S.L., Spain
Mondragon Health, Spain
Montero LS, Spain
MSD, United Kingdom
Namarel Ventures, Spain
Nanodecaldx SL, Spain
Nanoligent SL, Spain
Naru Intelligence, Spain
Navarra Health Cluster, Spain
Neuroscience Innovative Technologies, Spain
Norgestion, Spain
NOSO Capital SGEIC, Spain
Nucaps Nanotechnology, S.L., Spain
Oiarso S. Coop., Spain
Olavide Neuron STX, Spain
Onena Medicines, Spain
Oniria Therapeutics S.L., Spain
Optimus 3D, Spain
Oryzon Genomics, Spain
P-BIO, Portugal
Peaches S.L., Spain
Pharmacelera, Spain
Pioneering Ventures (Pioneer Group), United Kingdom
Prospera Biotech, Spain
Provincial Council of Gipuzkoa, Spain
QualitecFarma, Spain
Quan Capital, China/United States
Ramon y Cajal Health Research Institute IRYCIS, Spain
Regeneron Pharmaceuticals, United States
Science and Innovation Link Office (SILO), Spain
SmartBio Analytics, Spain
Sodena, Spain
Sound Bioventures, Denmark
SPRI Group, Spain
STAb Therapeutics, Spain
SurBio+, Germany
Swanlaab Venture Factory, Spain
SwedenBIO, Sweden
TargTex S.A., Portugal
Tecnalia, Spain
Telum Therapeutics, Spain
ThyTech, Spain
University of Navarra, Spain
Vaxdyn, Spain
Viralgen, Spain
Vive Biotech, Spain
Vivia Biotech, Spain
Vivo Capital, United States
Vivotecnia Research, Spain
Yafo Capital, China
Ysios Capital, Spain
Ysium Medical, Spain
Zahory Ventures, Spain
ZeCardio Therapeutics, Spain
ZETA GmbH, Austria
Zwiers Regulatory Consulting - ProductLife Group, France

General Information & Inquiries
Contact us